PMID- 10171107
OWN - NLM
STAT- MEDLINE
DCOM- 19920625
LR  - 20071115
IS  - 1050-6934 (Print)
IS  - 1050-6934 (Linking)
VI  - 1
IP  - 1
DP  - 1991
TI  - Osteoinductive biomaterials for medical implantation.
PG  - 53-77
AB  - The search for the ideal implant material continues since presently available 
      implants all have significant drawbacks. This paper reviews three studies that we 
      recently completed with bone-inducing implants. Long-term clinical follow-up of 
      75 allogeneic demineralized bone implants showed an average degree of resorption 
      of 49%. Implants used for dorsal nasal augmentation showed an average degree of 
      resorption of 50.7%, increasing to 82.5% after a 24-month follow-up. The efficacy 
      of demineralized bone implants is dependent on many factors including site of 
      implantation, method of preparation, etc. Transforming growth factor-beta 1 
      (TGF-beta 1) is a regulator of bone formation. We combined recombinant TGF-beta 1 
      with demineralized bone powder in a rabbit facial augmentation model. At 6 weeks, 
      there was evidence of increased bone formation in the implants containing 
      TGF-beta 1. Even though TGF-beta 1 can increase bone formation in demineralized 
      bone implants, the overall bone-inducing activity in these implants seems to be 
      suboptimal. Osteoinductive factor extract (OFE) is a partially purified bone 
      factor preparation that has been shown to form bone when implanted into rats. 
      Using a collagen/ceramic carrier, we implanted OFE into a rabbit facial 
      augmentation model. At 21 d, histomorphometry revealed numerous osteoblasts and 
      bone formation in the OFE implants. The bone-inducing activity of many partially 
      purified osteoinductive preparations such as OFE is probably due to Bone 
      Morphogenetic Protein-2A (BMP-2A), which has been shown to induce bone formation 
      in its recombinant form. Recombinant DNA methodology provides the technology 
      necessary to produce these molecules in their homogeneous form, permitting 
      evaluation of bone-inducing activity in a preparation free of contaminants. 
      Finally, the ideal carrier must be devised to permit safe and effective delivery 
      of recombinant bone-inducing factors.
FAU - Toriumi, D M
AU  - Toriumi DM
AD  - Division of Facial Plastic and Reconstructive Surgery, Department of 
      Otolaryngology-Head and Neck Surgery, University of Illinois College of Medicine 
      at Chicago 60612.
FAU - East, C A
AU  - East CA
FAU - Larrabee, W F
AU  - Larrabee WF
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Long Term Eff Med Implants
JT  - Journal of long-term effects of medical implants
JID - 9110830
RN  - 0 (Biocompatible Materials)
RN  - 0 (Plastics)
RN  - 0 (Transforming Growth Factor beta)
MH  - Animals
MH  - *Biocompatible Materials
MH  - *Bone Matrix
MH  - Bone Resorption
MH  - Cartilage
MH  - Evaluation Studies as Topic
MH  - Humans
MH  - Models, Biological
MH  - *Osseointegration
MH  - Plastics
MH  - *Prostheses and Implants
MH  - Rabbits
MH  - Rats
MH  - Surgery, Plastic
MH  - Transforming Growth Factor beta/physiology
EDAT- 1990/12/10 00:00
MHDA- 1990/12/10 00:01
CRDT- 1990/12/10 00:00
PHST- 1990/12/10 00:00 [pubmed]
PHST- 1990/12/10 00:01 [medline]
PHST- 1990/12/10 00:00 [entrez]
PST - ppublish
SO  - J Long Term Eff Med Implants. 1991;1(1):53-77.